​

Forte Biosciences Stock (NASDAQ:FBRX)

RevenueOwnershipFinancialsChart
Forte Biosciences by TradingView

Previous Close

$18.66

52W Range

$4.11 - $28.68

50D Avg

$11.59

200D Avg

$12.83

Market Cap

$28.27M

Avg Vol (3M)

$542.32K

Beta

1.46

Div Yield

-

FBRX Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11

IPO Date

Apr 13, 2017

Website

FBRX Performance

FBRX Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-32.49M$-13.90M$-21.49M
Net Income$-31.48M$-13.86M$-21.71M
EBITDA$-32.49M$-13.90M$-21.45M
Basic EPS-$-0.80$-1.55
Diluted EPS-$-0.80$-1.55

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q1 21May 11, 21 | 7:24 AM

Peer Comparison

TickerCompany
ABVCABVC BioPharma, Inc.
KTTAPasithea Therapeutics Corp.
ERASErasca, Inc.
EWTXEdgewise Therapeutics, Inc.
CCCCC4 Therapeutics, Inc.
RZLTRezolute, Inc.
HOWLWerewolf Therapeutics, Inc.
INDPIndaptus Therapeutics, Inc.
TPSTTempest Therapeutics, Inc.
CELCCelcuity Inc.